Safety and pharmacokinetics of GSK3494245, a highly selective Leishmaniasis kinetoplastid proteasome inhibitor for the treatment of visceral leishmaniasis: A Phase 1, randomized, single ascending dose escalation study in healthy participants
PLOS Neglected Tropical Diseases · 2026
DOI: 10.1371/journal.pntd.0014181 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS Neglected Tropical Diseases, 2026. Verfasst von Mischka Moodley und 11 weiteren Autor:innen. Beteiligte Einrichtung: Global Health Medicines R&D, GSK, London, United Kingdom. Hauptthemen laut MEDLINE: Leishmaniasis, Visceral, Antiprotozoal Agents, Proteasome Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK.
Abstract (Originalsprache)
Background
Visceral leishmaniasis (VL) is a neglected tropical disease caused by kinetoplastid parasites. If left untreated, VL has a case fatality >90%, making treatment essential for patient survival. Existing therapies have several limitations that impact treatment outcomes, including toxicity, requirement for parenteral administration, long treatment duration, and development of parasite resistance, driving the need for newer therapies. This Phase 1 first-time-in-human study evaluated the tolerability, safety, and pharmacokinetics (PK) of GSK3494245, a novel highly selective Leishmania kinetoplastid proteasome inhibitor. Methodology This was a randomized, double-blind, placebo-controlled, single ascending dose study evaluating the oral administration of GSK3494245 in healthy participants aged 18 to ≤55 years (NCT04504435). The study was conducted at a single center in the United Kingdom between October 2020 and January 2024.
Findings
GSK3494245 had an acceptable safety profile following administration of single doses of up to 240 mg in healthy male participants. All adverse events (AEs) were considered resolved or recovered, with most AEs being of mild or moderate severity. One serious AE of mild tachycardia was reported. The increase in exposure was slightly more than dose-proportional and approximately proportional under fasted and fed conditions, respectively. The median time to reach the maximum plasma concentration (C max ) ranged from 0.50 to 1.79 hours, and the geometric mean of the elimination half-life ranged from 1.04 to 2.27 hours. Two participants met the C max stopping criterion.
Conclusion
GSK3494245 showed an acceptable safety profile over the dose range studied. However, based on its observed PK profile, GSK3494245 is unlikely to achieve the effective dose while ensuring safe exposure within the once- or twice-daily monotherapy target product profile recommended by the Drugs for Neglected Diseases initiative. Clinical Trial Registration NCT Number ( www.clinicaltrials.gov ): NCT04504435 EudraCT, CTIS : 2019-004492-39
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Global Health Medicines R&D, GSK, London, United Kingdom.
- GSK Clinical Unit Cambridge, GSK, Cambridge, United Kingdom.
- Department of Medicine, Addenbrooke's Hospital, Cambridge University Hospitals and University of Cambridge, Cambridge, United Kingdom.
- Clinical Pharmacology, Modeling and Simulation, Parexel, Milan, Italy.
- Global Health, GSK, Stevenage, Hertfordshire, United Kingdom.
- Clinical Pharmacology, Modeling and Simulation, Parexel, Dublin, Ireland.
ORCID-Profile: Mischka Moodley
Förderung
- GSK
Zitieren
APA
Moodley, M., Kostapanos, M., Iavarone, L., Bracher, M., Lavezzi, S. M., Davy, M., Singh, P., Bhat, R., Wong, D., Sharma, H., Tan, L. K., & Miles, T. J. (2026). Safety and pharmacokinetics of GSK3494245, a highly selective Leishmaniasis kinetoplastid proteasome inhibitor for the treatment of visceral leishmaniasis: A Phase 1, randomized, single ascending dose escalation study in healthy participants. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0014181
Vancouver
Moodley M, Kostapanos M, Iavarone L, Bracher M, Lavezzi SM, Davy M, et al. Safety and pharmacokinetics of GSK3494245, a highly selective Leishmaniasis kinetoplastid proteasome inhibitor for the treatment of visceral leishmaniasis: A Phase 1, randomized, single ascending dose escalation study in healthy participants. PLOS Neglected Tropical Diseases. 2026. doi:10.1371/journal.pntd.0014181
BibTeX
@article{Moodley2026,
author = {Moodley, Mischka and Kostapanos, Michalis and Iavarone, Laura and Bracher, Marguerite and Lavezzi, Silvia M and Davy, Maria and Singh, Pooja and Bhat, Ramya and Wong, Deborah and Sharma, Hema and Tan, Lionel K and Miles, Timothy J},
title = {Safety and pharmacokinetics of GSK3494245, a highly selective Leishmaniasis kinetoplastid proteasome inhibitor for the treatment of visceral leishmaniasis: A Phase 1, randomized, single ascending dose escalation study in healthy participants},
journal = {PLOS Neglected Tropical Diseases},
year = {2026},
doi = {10.1371/journal.pntd.0014181}
}
EUVIMED